老年非小细胞肺癌患者化疗药物治疗进展

结合国内外相关文献资料分析老年非小细胞肺癌(NSCLC)患者化疗的必要性,第三代抗肿瘤药物和不同化疗方案的疗效,以及分子靶向药物在老年患者中的治疗进展情况.单药化疗仍然是老年晚期NSCLC 一线治疗方案;部分PS 评分佳的老年患者可采用含卡铂、低剂量顺铂联合方案化疗;分子靶向药物治疗因其口服方便及不良反应小,适用于高龄、PS 评分差或有明显合并症的老年晚期NSCLC 患者的一线治疗.化疗对老年晚期NSCLC 患者疗效好,单药化疗、含铂或不含铂联合化疗及靶向治疗疗效相似.

Progression of the chemotherapy drugs for non-small cell lung cancer in the elderly patients

According to relevant domestic and foreign literatures, the necessity of chemotherapy for non-small cell lung cancer, the different chemotherapy regimens and the efficacy of the third generation of anticancer and the progress of the molecular targeting agents in elderly patients with advanced NSCLC were summarized. The single agent chemotherapy should be used as the standard therapy for the elderly patients with advanced non-small cell lung cancer. That patients with good PS score can be given combination chemotherapy including carboplatin and low-dose cisplatin. Molecular targeting agents with oral convenience and less adverse reaction, should be used as first-line treatment in elderly patients with advanced NSCLC with old age, poor PS score, or obvious complications. Chemotherapy shows good effects in treatment of elderly patients with advanced NSCLC. Therapeutic effects of single agent, non-cisplatin combined group, cisplatin combined group and targeting therapy are similar.